Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7487343 | 1.00 | KEAP1 (0.61) | KEAP1NFE2L2KDM4EALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL3424525 | 0.99 | KEAP1 (0.63) | KEAP1NFE2L2KDM4EALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL3424522 | 0.99 | KEAP1 (0.63) | KEAP1NFE2L2KDM4EALDH1A1GAA | |
| SCHEMBL17061257 | 0.90 | KEAP1 (0.61) | KEAP1NFE2L2KDM4EALDH1A1GAA | |
| SCHEMBL16485615 | 0.90 | KEAP1 (0.61) | KEAP1NFE2L2KDM4EALDH1A1GAA | |
| SCHEMBL7488041 | 0.88 | LTA4H (0.70) | KDM4ELTA4HTBXAS1 | |
| SCHEMBL7488032 | 0.88 | LTA4H (0.70) | KDM4ELTA4HTBXAS1 | |
| SCHEMBL13460611 | 0.86 | KEAP1 (0.64) | KEAP1NFE2L2KDM4EALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL3424487 | 0.85 | TBXAS1 (0.57) | KEAP1NFE2L2KDM4EALDH1A1NPC1 | |
| SCHEMBL19025439 | 0.85 | TBXAS1 (0.55) | KDM4ELTA4HTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2907805-B1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECHNOLOGY CO LTD (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-9724333-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECH CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9321752-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-04-26 | — | — | US | disclosed |
| US-20150252029-A1 | Novel Pyrazole Derivative | GREEN TECH CO., LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| EP-2907805-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| WO-2010027280-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-03-11 | — | — | WO | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, PSEN1, MAPT | KEAP1 1626/4885NFE2L2 1662/4885KDM4E 4095/4885 |
| US-20150252029-A1 | Novel Pyrazole Derivative | PSEN2, PSEN1, MAPT | KEAP1 1626/4885NFE2L2 1662/4885KDM4E 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.